JVSPAC Acquisition Corp. (JVSA) Prices $50M IPO
by Marlena Haddad on 2024-01-19 at 6:14am

JVSPAC Acquisition Corp. (NASDAQ: JVSA) announced the pricing of its $50 million IPO this morning. Its units are expected to begin trading on the Nasdaq under the symbol “JVSAU” on Friday, January 19, 2024. After the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the Nasdaq under the symbols “JVSA” and “JVSAR”, respectively.

The company intends to combine with a target at the intersection of the lifestyle sectors and technology with a total enterprise value ranging from $100 million to $600 million. JVSPAC is led by CEO and Chairman Albert Wong and CFO Mr. Claudius Tsang.

Total SPAC deal count for 2024 year-to-date is now 1. This offering is expected to close on Tuesday, January 23, 2024.


Maxim Group LLC acted as sole book running manager in the offering. Loeb & Loeb LLP is serving as Issuer’s Counsel with Cavas Pavri, Esq. serving as Underwriter’s Counsel. Marcum Asia CPAs LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved